ADCT-402 is being developed for the treatment of CD19-expressing non-Hodgkin’s lymphoma and B-cell leukemia (Company Pipeline, ADC Therapeutics, APR 19, 2016, View Source [SID:1234511064]). ADCT-402 is composed of a humanized antibody directed against human CD19, conjugated to a potent PBD dimer toxin. We have reported preclinical data demonstrating potent antitumor activity of ADCT-402 against CD19-expressing B-cell malignancies.1
CD19 expression has been demonstrated in many types of Non-Hodgkin lymphoma2 including Burkitt’s Lymphoma, Follicular Lymphoma and Diffuse Large B-cell Lymphoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!